

Tauopathy drugs for neurodegenerative diseases could take off after first-to-market drug is launched

Écrit par GlobalData

Mercredi, 22 Février 2017 15:19 -

GlobalData 

The tauopathies market, which covers more than 20 neurodegenerative diseases such as progressive

The company's [latest report](#) states that once the first drug in the tauopathies market is approved

Akiko Fukui, MSc, Healthcare Analyst for GlobalData, explains: “There are currently no approved therapies

“The first drug will set an example for effective mechanisms of action (MOAs), regulatory processes, and

If a disease-modifying approach is approved, patients’ lives will be extended and this will provide a basis

Fukui continues: “The possibility of expanding sales from the tauopathies market into the much larger Alzheimer’s

GlobalData has identified four products in the late-stage pipeline that are currently in development as the